Cell重磅突破：刘兴国/龙琪团队首创「线粒体胶囊移植」新技术，为线粒体遗传病、帕金森病等重大疾病带来治疗新思路

Core Viewpoint - The article discusses a groundbreaking study on mitochondrial transplantation, which presents a new therapeutic approach for mitochondrial diseases and neurodegenerative disorders such as Parkinson's disease, leveraging encapsulated mitochondria for effective treatment [4][6][10]. Group 1: Research Findings - The study developed a new technique for mitochondrial encapsulation, allowing for efficient in vivo transplantation of mitochondria, significantly improving symptoms in models of Parkinson's disease, Leigh syndrome, and mitochondrial DNA depletion syndrome [5][10]. - The research introduces the concept of "organelle therapy," providing a novel treatment strategy for mitochondrial genetic diseases and neurodegenerative disorders [6][10]. - The encapsulation method utilizes red blood cell membranes to create "mitochondrial capsules," which protect the mitochondria and enhance their delivery into recipient cells, achieving a transplantation efficiency of approximately 80% compared to less than 5% for bare mitochondria [7][10]. Group 2: Implications and Applications - Mitochondrial transplantation can repair mitochondrial defects in patient-derived cells and is effective in treating mitochondrial DNA depletion syndrome and Leigh syndrome [8][10]. - In mouse models of Parkinson's disease, mitochondrial transplantation effectively prevented neuronal death and restored normal mitochondrial function, significantly improving motor abilities [10][11]. - This organelle therapy approach offers a more precise strategy compared to traditional cell therapies, potentially benefiting a wide range of diseases associated with mitochondrial dysfunction, including neurodegenerative diseases and metabolic disorders [10][11].